Who
Maykin Ho
Director
Company insider
Files Form 4 as: Director, Agios Pharmaceuticals; Director, Kyntra Bio; Director, BioMarin Pharmaceutical; Director, Neumora Therapeutics; Director, Parexel International.
In numbers
- Trades disclosed
- 93
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $149K
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 23 Jun 2015
- Last trade
- 18 Jun 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,816 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,816 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,927 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,816 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,927 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,950 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,950 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,816 at $0.00 | filing |
| 12 Jun 2026filed 17 Jun 2026 | KYNB Kyntra Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —7,000 at $0.00 | filing |
| 12 Jun 2026filed 17 Jun 2026 | KYNB Kyntra Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —7,000 at $0.00 | filing |
| 2 Jun 2026filed 4 Jun 2026 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | —7,490 at $0.00 | filing |
| 2 Jun 2026filed 4 Jun 2026 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | —7,490 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 20 Jun 2025filed 23 Jun 2025 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,120 at $0.00 | filing |
| 20 Jun 2025filed 23 Jun 2025 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,120 at $0.00 | filing |
| 18 Jun 2025filed 23 Jun 2025 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,816 at $0.00 | filing |
| 18 Jun 2025filed 23 Jun 2025 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,768 at $0.00 | filing |
| 4 Jun 2025filed 6 Jun 2025 | KYNB Kyntra Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 28 May 2025filed 30 May 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —95,586 | filing |
News
Kyntra Bio (KYNB): Can Its New Strategy And Pipeline Revive Investor Interest?KYNB · rttnews.com · 19 Oct 2026Kyntra Bio Inc (KYNB) – What Are Brokerages Saying About This Stock?KYNB · dailypolitical.com · 14 Oct 2026Prothena (NASDAQ:PRTA) vs. Kyntra Bio (NASDAQ:KYNB) Financial ReviewKYNB · dailypolitical.com · 12 Oct 2026
0 headlines in the last 90 days name Maykin Ho; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.